The first artificial intelligence (AI) endoscopy module developed specifically to help detect adenomas during routine colonoscopy is making its debut…
Home »
White Bagging: Insurer Shift on Drugs Raises Alarm
A big change in drug treatment for cancer is arriving in Georgia. It’s not a new medication. What’s coming is something…
Adverse Reactions to Immunotherapy Can Appear After a Year
Clinicians should be on the lookout for immune-related adverse reactions (irAEs) even after patients have been receiving anti–programmed cell death…
Genetic Testing for Breast and Ovarian Cancer
A large, retrospective study shows how germline genetic testing has evolved over time in women with breast or ovarian cancer…
Nivolumab-Cabozantinib Boosts Survival in Kidney Cancer
NEW YORK (Reuters Health) – Previously untreated patients with advanced renal-cell carcinoma live twice as long without disease progression when…
Vir, GSK to Halt Enrollment in US COVID-19 Antibody Trial Substudy
Vir Biotechnology and Britain’s GSK said on Wednesday they would pause enrollment into a study testing their experimental COVID-19 antibody…
Remission of Hodgkin Lymphoma After COVID-19
Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. Patients with cancer are considered at…
Adjuvant Nivolumab: A New Standard of Care in High-risk MIUC?
The checkpoint inhibitor nivolumab is efficacious and well tolerated when used as adjuvant therapy in patients who have undergone radical…
Nearly 4 in 10 Cancer Deaths Attributable to Cigarette Smoking
Although rates of smoking have been declining in the United States, smoking is still contributing substantially to the cancer burden,…
FDA Approves Libtayo (cemiplimab-rwlc) as First Immunotherapy Indicated for Patients with Advanced Basal Cell Carcinoma
TARRYTOWN, N.Y. and PARIS, Feb. 9, 2021 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S.…